BIRMINGHAM, Ala., Nov. 15 /PRNewswire/ -- BioHorizons Implant Systems, Inc. has introduced a new line of Tapered Internal Implants that feature a unique thread design and proven surface engineering technology. This product introduction is the first from BioHorizons to address the tapered market segment which account for over 50% of the U.S. dental implant market.
The Tapered Internal Implants incorporate the Laser-Lok(R) precision laser collar surface treatment, which controls cellular growth and directs hard and soft tissue attachment onto dental implants. The result of over 15 years of evidence-based research and documented clinical trials, the patented 8 and 12 micron Laser-Lok(R) channels play a vital role in inhibiting epithelial downgrowth and attaching and retaining crestal bone. The implant design and surface treatment displayed improved hard and soft tissue response leading to excellent esthetic results in animal and human clinical trials.
"These new implants will offer supreme esthetic and clinical results to our global dental implant customers," commented Steve Boggan, President and CEO of BioHorizons. "Building on BioHorizons' commitment to science, innovation and service, we are pleased to bring such a novel product to the dental implant industry."
BioHorizons was founded in 1994 as an incubator company at the University of Alabama at Birmingham. BioHorizon's flagship External Implant System, a patented system of dental implants and related products, was launched in 1997. The Company was purchased by HealthpointCapital in 2006. BioHorizons has a strong product offering of dental implants including internal hex, external hex, overdenture and one-piece implants. BioHorizons has signed exclusive distribution agreements with LifeCell Corp. and Osteotech, Inc. to market their allograft regeneration products to the dental community. With 217 employees, BioHorizons has grown into one of the largest dental implant companies in the world. The company has a direct sales force in the U.S., Canada, Germany, Spain and United Kingdom. Products are distributed in the rest of the world via a network of independent distributors. http://www.biohorizons.com
HealthpointCapital is a values-driven, research-based private equity firm exclusively focused on the musculoskeletal sector -- specifically orthopedics and dental.
Our cumulative 85 years of experience in healthcare technology, research and private investing helps our clients capitalize on the explosive growth and unique investment opportunities in one of the fastest growing sectors of the medical device industry.
HealthpointCapital manages $650 million of institutional capital. http://www.healthpointcapital.com
Contact: Steve Boggan, President and CEO of BioHorizons, (205) 967-7880.
|SOURCE BioHorizons Implant Systems, Inc.|
Copyright©2007 PR Newswire.
All rights reserved